A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

This study tests two immunotherapy drugs — durvalumab and monalizumab — for bladder cancer that has not spread into the muscle wall (non-muscle-invasive bladder cancer). It is designed for patients whose cancer has not responded to or has come back after BCG treatment, a standard bladder cancer therapy, and who cannot or prefer not to have their bladder removed. **You may be eligible if...** - You are 18 or older with high-grade bladder cancer confined to the inner lining (not the muscle) - Your cancer has not responded to or has returned after BCG therapy - You are unable or unwilling to have your bladder surgically removed - Your visible tumor was completely removed before joining the study - You have adequate kidney, liver, and blood function **You may NOT be eligible if...** - You have previously received PD-1 or PD-L1 immunotherapy drugs - You have active autoimmune disease requiring treatment (e.g., lupus, inflammatory bowel disease) - You have evidence of cancer that has spread beyond the bladder - You are pregnant or breastfeeding - You have active hepatitis B, active hepatitis C, or untreated HIV with detectable virus Talk to your doctor to see if this trial is right for you.